imatinib mesylate has been researched along with Chromosome Deletion in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (63.33) | 29.6817 |
| 2010's | 11 (36.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hasegawa, D; Iijima, K; Ishida, T; Kishimoto, K; Kosaka, Y; Kozaki, A; Matsumoto, H; Mori, T; Nakamachi, Y; Nino, N; Nishimura, N; Saegusa, J; Saito, A; Sakaguchi, K; Shono, A; Tahara, T; Takafuji, S; Tamura, A; Uemura, S; Yamamoto, N; Yokoi, T | 1 |
| Chandrakala, S; Ghosh, K; Joshi, D; Korgaonkar, S; Vundinti, BR | 1 |
| Chopra, A; Gogia, A; Jha, A; Kumar, R; Mallik, N | 1 |
| Fujisawa, S; Hagihara, M; Ishigatsubo, Y; Ishii, Y; Itabashi, M; Kajiyama, R; Matsumoto, K; Motohashi, K; Numata, A; Yamamoto, W | 1 |
| Angelini, S; Astolfi, A; Biasco, G; Nannini, M; Pantaleo, MA; Ravegnini, G | 1 |
| Chang, H; Kamel-Reid, S; Kim, DH; Lipton, JH; Messner, HA; Popradi, G; Sriharsha, L | 1 |
| Baeumler, J; Falkenburg, JH; Nijmeijer, BA; Ottmann, OG; Szuhai, K; van Schie, ML | 1 |
| Colombo, D; Finelli, P; Giardino, D; Larizza, L; Malvestiti, F; Perego, D; Rodeschini, O | 1 |
| Ceglerek, B; Grygalewicz, B; Konopka, L; Krawczyk, P; Pastwińska, A; Pieńkowska-Grela, B; Rygier, J; Seferyńska, I; Sikorska, A; Woroniecka, R | 1 |
| Godley, LA | 1 |
| Hackanson, B; Lübbert, M; Rückert, A | 1 |
| Abe, T; Aizawa, Y; Furukawa, T; Karimata, K; Kozakai, T; Masuko, M; Moriyama, M; Shibasaki, Y; Toba, K; Ushiki, T; Yano, T | 1 |
| Kawasaki, Y; Nakazora, T; Shinohara, K; Suzukawa, M; Tominaga, T | 1 |
| Ben Youssef, Y; Bennour, A; Elloumi, M; Harrabi, I; Khelif, A; Laatiri, MA; Meddeb, B; Ouahchi, I; Saad, A; Sennana, H; Zaier, M | 1 |
| Hamilton, MS; Hunter, H; Kerr, JP; Tucker, D; Wickham, C | 1 |
| Harn, L; Najera, JE | 1 |
| Chi, HS; Cho, YU; Im, HJ; Jang, S; Park, CJ; Park, SH | 1 |
| Schwartz, RS | 1 |
| Alam, R; Boogaerts, M; Clark, J; Cools, J; Cortes, J; Coutre, SE; Cross, NC; DeAngelo, DJ; Galinsky, I; Gilliland, DG; Gotlib, J; Griffin, JD; Kantarjian, H; Kutok, J; Legare, RD; Malone, J; Marynen, P; Rose, M; Schmid, J; Schrier, SL; Stone, R; Stover, EH; Tefferi, A; Vandenberghe, P; Verhoef, G; Wlodarska, I | 1 |
| Bown, N; Brizard, A; Byrne, J; Clark, RE; Cuthbert, G; Deininger, MW; Franke, C; Freeman-Edward, J; Green, AR; Guilhot, F; Hennig, E; Huntly, BJ; Nacheva, EP; Niederwieser, D; Reid, AG; Vassiliou, G | 1 |
| Cogan, E; Goldman, M; Roufosse, FE | 1 |
| Friedrich, MJ | 1 |
| Baron, F; Bours, V; Croisiau, C; Herens, C; Tassin, F | 1 |
| Tefferi, A | 1 |
| Bekele, BN; Cortes, J; Garcia-Manero, G; Glassman, A; Hayes, K; Kantarjian, H; O'Brien, S; Quintas-Cardama, A; Rios, MB; Talpaz, M; Verstovsek, S; Zhou, X | 1 |
| Barete, S; Blanchet, O; Bletry, O; Cambier, N; Demarty, AL; Dib, M; Drupt, F; Fenaux, P; Gardembas, M; Hachulla, E; Hatron, PY; Kahn, JE; Laï, JL; Lepers, S; Libersa, C; Maloum, K; Philippe, N; Preudhomme, C; Prin, L; Quesnel, B; Roche-Lestienne, C; Rose, C; Roumier, AS; Soenen-Cornu, V | 1 |
| Cools, J | 1 |
| Aventin, A; Beacci, D; Cuneo, A; Foppoli, M; Invernizzi, R; La Starza, R; Luciano, L; Martelli, MF; Marynen, P; Mecucci, C; Nozzoli, C; Sambani, C; Specchia, G; Testoni, N | 1 |
| Calabrese, G; Di Gianfilippo, R; Di Lorenzo, R; Fantasia, D; Palka, G; Stuppia, L | 1 |
| Donti, E; Gozzetti, A; Ronconi, S; Spedicato, F; Valenti, AM; Zaccaria, A | 1 |
2 review(s) available for imatinib mesylate and Chromosome Deletion
| Article | Year |
|---|---|
miRNA profiling in gastrointestinal stromal tumors: implication as diagnostic and prognostic markers.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Chromosome Deletion; Chromosomes, Human, Pair 14; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; MicroRNAs; Mutation; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Transcriptome | 2015 |
Hyperleukocytotic secondary acute myeloid leukemia (AML) with sole monosomy 7 as sequela of Philadelphia-chromosome positive chronic myeloid leukemia (CML).
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 7; Cytarabine; Disease Progression; Fatal Outcome; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Leukocytosis; Male; Monosomy; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Selection, Genetic | 2009 |
4 trial(s) available for imatinib mesylate and Chromosome Deletion
| Article | Year |
|---|---|
Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients.
Topics: Adolescent; Adult; Aged; Benzamides; Child; Child, Preschool; Chromosome Deletion; Chromosomes, Artificial, Bacterial; Chromosomes, Human, Pair 9; Down-Regulation; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; MicroRNAs; Middle Aged; Piperazines; Pyrimidines; Young Adult | 2014 |
Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions.
Topics: Adult; Antineoplastic Agents; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 9; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Risk Factors; Survival Analysis; Treatment Outcome | 2003 |
A novel pathogenetic mutation in clonal eosinophilia.
Topics: Benzamides; Cell Division; Cell Line, Transformed; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 4; Clone Cells; DNA Mutational Analysis; Eosinophilia; Humans; Imatinib Mesylate; Inhibitory Concentration 50; mRNA Cleavage and Polyadenylation Factors; Mutation; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Translocation, Genetic | 2004 |
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 9; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Treatment Outcome | 2005 |
24 other study(ies) available for imatinib mesylate and Chromosome Deletion
| Article | Year |
|---|---|
ETV6-ABL1 fusion combined with monosomy 7 in childhood B-precursor acute lymphoblastic leukemia.
Topics: Adolescent; Chromosome Deletion; Chromosomes, Human, Pair 7; Dasatinib; ETS Translocation Variant 6 Protein; Female; Gene Fusion; Gene Rearrangement; Humans; Imatinib Mesylate; Induction Chemotherapy; Leukemia, B-Cell; Maintenance Chemotherapy; Oncogene Proteins v-abl; Oncogene Proteins, Fusion; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-ets; Remission Induction; Repressor Proteins | 2018 |
Development of myelodysplastic syndrome in a patient with chronic myelogenous leukemia treated with imatinib.
Topics: Antineoplastic Agents; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 20; Chromosomes, Human, Pair 7; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Monosomy; Myelodysplastic Syndromes | 2015 |
Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation.
Topics: Adult; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 20; Female; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Remission Induction; Treatment Outcome | 2016 |
No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 9; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; RNA, Messenger; Treatment Failure; Treatment Outcome | 2008 |
Establishment and cytogenetic characterization of a human acute lymphoblastic leukemia cell line (ALL-VG) with ETV6/ABL1 rearrangement.
Topics: Adult; Benzamides; Cell Line, Tumor; Cell Survival; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 6; Cytogenetic Analysis; Dose-Response Relationship, Drug; Genes, abl; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Male; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Sensitivity and Specificity; Translocation, Genetic | 2008 |
Fluorescence in situ hybridization dissection of a chronic myeloid leukemia case bearing the apparently balanced translocations (9;22)(q34;q11.2) and (11;11)(p15;q13).
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow Cells; Chromosome Deletion; Chromosome Mapping; Chromosome Painting; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Gene Rearrangement; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Piperazines; Pyrimidines; Translocation, Genetic; Tumor Cells, Cultured | 2009 |
Karyotype changes during long-term targeted therapy of chronic myeloid leukemia with imatinib.
Topics: Antineoplastic Agents; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Risk Factors; Time Factors; Translocation, Genetic; Treatment Outcome | 2009 |
Deletion of the der(9q) in chronic myeloid leukemia: the controversy continues.
Topics: Antineoplastic Agents; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Disease Progression; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Risk Factors; Translocation, Genetic; Treatment Outcome | 2009 |
Myelodysplastic syndrome with Ph negative monosomy 7 chromosome following transient bone marrow dysplasia during imatinib treatment for chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 7; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Myelodysplastic Syndromes; Piperazines; Pyrimidines | 2011 |
[Acute leukemia of ambiguous lineage with monosomy 7 and Philadelphia chromosome].
Topics: Acute Disease; Aged; Antineoplastic Agents; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 7; Diagnosis, Differential; Fatal Outcome; Female; Heart Failure; Humans; Imatinib Mesylate; Leukemia; Philadelphia Chromosome; Piperazines; Pyrimidines | 2011 |
Molecular cytogenetic study of derivative chromosome 9 deletion in chronic myeloid leukemia patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; DNA Probes; Female; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-bcr; Pyrimidines; Retrospective Studies; Translocation, Genetic | 2012 |
Lytic bone disease as the presenting feature of Philadelphia-positive monosomy 7 myelodysplasia progressing to acute myeloid leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Diseases; Chromosome Deletion; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 7; Chromosomes, Human, Pair 9; Cytarabine; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pain; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Radiography; Vidarabine | 2012 |
Chronic eosinophilic leukemia presenting with mouth and penile ulcers.
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow Examination; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 4; Diagnosis, Differential; Eosinophils; Gene Fusion; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukocyte Count; Male; mRNA Cleavage and Polyadenylation Factors; Oral Ulcer; Penile Diseases; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Ulcer | 2012 |
A case with coexistence of major and minor BCR/ABL fusion transcript at lymphoblastic crisis of chronic myelogenous leukemia in patients with major BCR/ABL positivity during chronic phase.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 7; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunophenotyping; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Real-Time Polymerase Chain Reaction | 2013 |
The hypereosinophilic syndrome and the biology of cancer.
Topics: Benzamides; Chromosome Deletion; Enzyme Inhibitors; Eosinophilia; Eosinophils; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; T-Lymphocytes; Translocation, Genetic | 2003 |
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
Topics: Adult; Base Sequence; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 4; Enzyme Inhibitors; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; Molecular Sequence Data; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Recombination, Genetic; Remission Induction | 2003 |
Hypereosinophilic syndrome.
Topics: Benzamides; Chromosome Deletion; Clone Cells; Enzyme Inhibitors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Interleukin-5; Phenotype; Piperazines; Pyrimidines; Recombination, Genetic; T-Lymphocytes | 2003 |
From bedside to bench: treatment for rare blood disorder yields clues to disease mechanism.
Topics: Antineoplastic Agents; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 4; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oncogene Proteins, Fusion; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Platelet-Derived Growth Factor | 2003 |
Clonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases.
Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Chromosome Deletion; Chromosome Mapping; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Piperazines; Pyrimidines | 2003 |
Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Base Sequence; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 4; Cytogenetic Analysis; Exons; Female; France; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interleukin-5; Male; Middle Aged; Molecular Sequence Data; Piperazines; Pyrimidines; Sequence Analysis, DNA; Serine Endopeptidases; Tryptases | 2005 |
The hypereosinophilic syndrome: idiopathic or not, that is the question.
Topics: Antineoplastic Agents; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 4; Chronic Disease; Clone Cells; Diagnosis, Differential; Drug Resistance, Neoplasm; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Lymphoproliferative Disorders; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Staurosporine; T-Lymphocyte Subsets | 2005 |
The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Benzamides; Bone Marrow Cells; Child; Chromosome Deletion; Chromosomes, Human, Pair 4; Drug Therapy, Combination; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Organ Specificity; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Survival Analysis | 2005 |
Fluorescence in situ hybridization analysis of minimal residual disease and the relevance of the der(9) deletion in imatinib-treated patients with chronic myeloid leukemia.
Topics: Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 9; Follow-Up Studies; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Piperazines; Pyrimidines | 2006 |
Persistence of chromosomal abnormalities additional to the Philadelphia chromosome after Philadelphia chromosome disappearance during imatinib therapy for chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Aneuploidy; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Chromosome Deletion; Clone Cells; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Monosomy; Neoplastic Cells, Circulating; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines; Remission Induction; Trisomy | 2007 |